95 related articles for article (PubMed ID: 30745556)
1. [Recurrence of malignant lymphoma immediately after treatment for hepatitis C virus using direct-acting antivirals].
Iwane K; Kayahara T; Takabatake H; Morimoto Y; Iseki A; Mizuno M; Notohara K
Nihon Shokakibyo Gakkai Zasshi; 2019; 116(2):177-183. PubMed ID: 30745556
[TBL] [Abstract][Full Text] [Related]
2. Direct-Acting Antivirals in Hepatitis C Virus-Associated Diffuse Large B-cell Lymphomas.
Merli M; Frigeni M; Alric L; Visco C; Besson C; Mannelli L; Di Rocco A; Ferrari A; Farina L; Pirisi M; Piazza F; Loustaud-Ratti V; Arcari A; Marino D; Sica A; Goldaniga M; Rusconi C; Gentile M; Cencini E; Benanti F; Rumi MG; Ferretti VV; Grossi P; Gotti M; Sciarra R; Tisi MC; Cano I; Zuccaro V; Passamonti F; Arcaini L
Oncologist; 2019 Aug; 24(8):e720-e729. PubMed ID: 30552159
[TBL] [Abstract][Full Text] [Related]
3. Development of diffuse large B-cell lymphoma after sofosbuvir-ledipasvir treatment for chronic hepatitis C: A case report and literature review.
Sakai H; Miwa T; Ikoma Y; Hanai T; Nakamura N; Imai K; Kitagawa J; Shirakami Y; Kanemura N; Suetsugu A; Takai K; Shiraki M; Shimizu M
Mol Clin Oncol; 2020 Sep; 13(3):1. PubMed ID: 32754315
[TBL] [Abstract][Full Text] [Related]
4. Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma.
Merli M; Defrancesco I; Visco C; Besson C; Di Rocco A; Arcari A; Sica A; Cencini E; Tisi MC; Frigeni M; Grossi P; Bianchi B; Mora B; Bertù L; Bruno R; Passamonti F; Arcaini L
Leuk Lymphoma; 2020 Sep; 61(9):2122-2128. PubMed ID: 32343165
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma.
Tsutsumi Y; Nakayama C; Kamada K; Kikuchi R; Kudo D; Ito S; Matsuoka S; Shiratori S; Yamamoto Y; Naruse H; Teshima T
Ann Hematol; 2017 Dec; 96(12):2057-2061. PubMed ID: 28939993
[TBL] [Abstract][Full Text] [Related]
6. Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana Linfomi.
Merli M; Rattotti S; Spina M; Re F; Motta M; Piazza F; Orsucci L; Ferreri AJM; Perbellini O; Dodero A; Vallisa D; Pulsoni A; Santoro A; Sacchi P; Zuccaro V; Chimienti E; Russo F; Visco C; Zignego AL; Marcheselli L; Passamonti F; Luminari S; Paulli M; Bruno R; Arcaini L;
J Clin Oncol; 2022 Dec; 40(35):4060-4070. PubMed ID: 35714311
[TBL] [Abstract][Full Text] [Related]
7. Real-world effectiveness of sofosbuvir-based treatment regimens for chronic hepatitis C genotype 3 infection: Results from the multicenter German hepatitis C cohort (GECCO-03).
Wehmeyer MH; Ingiliz P; Christensen S; Hueppe D; Lutz T; Simon KG; Schewe K; Boesecke C; Baumgarten A; Busch H; Rockstroh J; Schmutz G; Kimhofer T; Berger F; Mauss S; Schulze Zur Wiesch J
J Med Virol; 2018 Feb; 90(2):304-312. PubMed ID: 28710853
[TBL] [Abstract][Full Text] [Related]
8. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hepatitis C virus recurrence after transplantation with sofosbuvir/ledipasvir: The role of ribavirin.
Globke B; Raschzok N; Teegen EM; Pratschke J; Schott E; Eurich D
Transpl Infect Dis; 2017 Feb; 19(1):. PubMed ID: 27943544
[TBL] [Abstract][Full Text] [Related]
10. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
Adhoute X; Penaranda G; Raoul JL; Sellier F; Castellani P; Oules V; Perrier H; Lefolgoc G; Pol B; Campanile M; Bayle O; Beaurain P; Monnet O; Bourlière M
Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):368-375. PubMed ID: 29384796
[TBL] [Abstract][Full Text] [Related]
11. Interferon-free therapies for patients with chronic hepatitis C genotype 3 infection: A systematic review.
Gimeno-Ballester V; Buti M; San Miguel R; Riveiro M; Esteban R
J Viral Hepat; 2017 Nov; 24(11):904-916. PubMed ID: 27925386
[TBL] [Abstract][Full Text] [Related]
12. Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma.
Occhipinti V; Farina L; Viganò M; Capecchi M; Labanca S; Fanetti I; Corradini P; Rumi M
Dig Liver Dis; 2019 May; 51(5):719-723. PubMed ID: 30502232
[TBL] [Abstract][Full Text] [Related]
13. Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C.
Izzo I; Zanotti P; Chirico C; Casari S; Villanacci V; Salemme M; Biasi L; Festa E; Castelli F
Infection; 2016 Dec; 44(6):811-812. PubMed ID: 27311809
[TBL] [Abstract][Full Text] [Related]
14. Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.
Rupp C; Hippchen T; Neuberger M; Sauer P; Pfeiffenberger J; Stremmel W; Gotthardt DN; Mehrabi A; Weiss KH
World J Gastroenterol; 2018 Mar; 24(12):1353-1360. PubMed ID: 29599610
[TBL] [Abstract][Full Text] [Related]
15. Aggressive recurrence of Non-Hodgkin's Lymphoma after successful clearance of hepatitis C virus with direct acting antivirals.
Samonakis DN; Psyllaki M; Pavlaki KI; Drakos E; Kehagias E; Tzardi M; Papadaki HA
Ann Hepatol; 2021; 21():100141. PubMed ID: 31694799
[TBL] [Abstract][Full Text] [Related]
16. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K
J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183
[TBL] [Abstract][Full Text] [Related]
17. Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort.
Idilman R; Demir M; Aladag M; Erol C; Cavus B; Iliaz R; Koklu H; Cakaloglu Y; Sahin M; Ersoz G; Koksal İ; Karasu Z; Ozgenel M; Turan İ; Gunduz F; Ataseven H; Akdogan M; Kiyici M; Koksal AS; Akhan S; Gunsar F; Tabak F; Kaymakoglu S; Akarca US;
J Viral Hepat; 2019 Jun; 26(6):666-674. PubMed ID: 30740820
[TBL] [Abstract][Full Text] [Related]
18. The influence of immunosuppressants on direct-acting antiviral therapy is dependent on the hepatitis C virus genotype.
Frey A; Piras-Straub K; Walker A; Timm J; Gerken G; Herzer K
Transpl Infect Dis; 2018 Feb; 20(1):. PubMed ID: 29111569
[TBL] [Abstract][Full Text] [Related]
19. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.
Romano A; Angeli P; Piovesan S; Noventa F; Anastassopoulos G; Chemello L; Cavalletto L; Gambato M; Russo FP; Burra P; Vincenzi V; Scotton PG; Panese S; Tempesta D; Bertin T; Carrara M; Carlotto A; Capra F; Carolo G; Scroccaro G; Alberti A
J Hepatol; 2018 Aug; 69(2):345-352. PubMed ID: 29551707
[TBL] [Abstract][Full Text] [Related]
20. Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.
Virlogeux V; Pradat P; Hartig-Lavie K; Bailly F; Maynard M; Ouziel G; Poinsot D; Lebossé F; Ecochard M; Radenne S; Benmakhlouf S; Koffi J; Lack P; Scholtes C; Uhres AC; Ducerf C; Mabrut JY; Rode A; Levrero M; Combet C; Merle P; Zoulim F
Liver Int; 2017 Aug; 37(8):1122-1127. PubMed ID: 28423231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]